Effect of apolipoprotein e and butyrylcholinesterase genotypes on cognitive response to cholinesterase inhibitor treatment at different stages of Alzheimer's disease

Pharmacogenomics Journal

Volumn 11, Issue 6, 2011, Pages 444-450

  Patterson, C E ^a   Todd, S A ^a,b   Passmore, A P ^a,b  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Alzheimer's disease; apolipoprotein E; butyrylcholinesterase; cholinesterase inhibitor

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E4; CHOLINESTERASE; CHOLINESTERASE INHIBITOR;

ADULT; AGED; ALZHEIMER DISEASE; APOE GENE; ARTICLE; BCHE GENE; COGNITION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME INHIBITION; FEMALE; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HEREDITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; ONSET AGE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN FUNCTION; SCORING SYSTEM; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; COGNITION; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PSYCHOLOGICAL TESTS;

EID: 81755189086     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.61     Document Type: Article

References (68)

1. World Health Organization. World Health Report 2003-Shaping the Future. WHO: Geneva, 2003.
2. National Collaborating Centre for Mental Health. Dementia: a NICE-SCIE Guideline on Supporting People with Dementia and their Carers in Health and Social Care 2007.
3. Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-2117. (Pubitemid 41797645)
4. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976; 2: 1403. (Pubitemid 8004505)
5. Bartus RT, Dean III RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-414.
6. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 1982; 215: 1237-1239. (Pubitemid 12106486)
7. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; 1: CD005593.
8. Emre M. Switching cholinesterase inhibitors in patients with Alzheimer's disease. Int J Clin Pract Suppl 2002; 127: 64-72. (Pubitemid 34778531)
9. Cacabelos R. Pharmacogenomics and therapeutic prospects in dementia. Eur Arch Psychiatry Clin Neurosci 2008; 258(Suppl 1): 28-47. (Pubitemid 351424036)
10. Saunders AM, Schmader K, Breitner JC, Benson MD, Brown WT, Goldfarb L et al. Apolipoprotein E epsilon 4 allele distributions in late-onset Alzheimer's disease and in other amyloid-forming diseases. Lancet 1993; 342: 710-711. (Pubitemid 23279765)
11. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995; 92: 12260-12264. (Pubitemid 26014050)
12. Craft S, Teri L, Edland SD, Kukull WA, Schellenberg G, McCormick WC et al. Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. Neurology 1998; 51: 149-153. (Pubitemid 28345375)
13. Mortensen EL, Hogh P. A gender difference in the association between APOE genotype and age-related cognitive decline. Neurology 2001; 57: 89-95. (Pubitemid 32634855)
14. Farlow MR, Lahiri DK, Poirier J, Davignon J, Hui S. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann N Y Acad Sci 1996; 802: 101-110. (Pubitemid 27055504)
15. Farlow MR, Lahiri DK, Poirier J, Davignon J, Schneider L, Hui SL. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology 1998; 50: 669-677.
16. Lucotte G, Oddoze C, Michel B. Apolipoprotein E genotype allele e4 and response to tacrine in Alzheimer's disease. Alzheimer's Res 1996; 2: 101-102. (Pubitemid 26254455)
17. MacGowan SH, Wilcock GK, Scott M. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. Int J Geriatr Psychiatry 1998; 13: 625-630. (Pubitemid 28441962)
18. Oddoze C, Michel B, Lucotte G. Apolipoprotein E4 allele predicts a better response to donepezil therapy in Alzheimer's disease. Alzheimer's Rep 2000; 3: 213-216.
19. Bizzarro A, Marra C, Acciarri A, Valenza A, Tiziano FD, Brahe C et al. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease. Dement Geriatr Cogn Disord 2005; 20: 254-261. (Pubitemid 41291577)
20. Choi SH, Kim SY, Na HR, Kim BK, Yang DW, Kwon JC et al. Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 2008; 25: 445-450. (Pubitemid 351630078)
21. Farlow MR, Cyrus PA, Nadel A, Lahiri DK, Brashear A, Gulanski B. Metrifonate treatment of AD: influence of APOE genotype. Neurology 1999; 53: 2010-2016.
22. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000; 321: 1445-1449.
23. Rigaud AS, Traykov L, Caputo L, Guelfi MC, Latour F, Couderc R et al. The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer's disease. Eur J Neurol 2000; 7: 255-258. (Pubitemid 32250657)
24. Aerssens J, Raeymaekers P, Lilienfeld S, Geerts H, Konings F, Parys W. APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001; 12: 69-77. (Pubitemid 32149710)
25. Almkvist O, Jelic V, Amberla K, Hellstrom-Lindahl E, Meurling L, Nordberg A. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients. Dement Geriatr Cogn Disord 2001; 12: 22-32. (Pubitemid 32008938)
26. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Donepezil Nordic Study Group. A 1-year, randomized, placebocontrolled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-495. (Pubitemid 32757598)
27. Rigaud AS, Traykov L, Latour F, Couderc R, Moulin F, Forette F. Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease. Pharmacogenetics 2002; 12: 415-420. (Pubitemid 34816421)
28. Visser PJ, Scheltens P, Pelgrim E, Verhey FR, Dutch ENA-NL-01 Study Group. Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients. Dement Geriatr Cogn Disord 2005; 19: 126-133. (Pubitemid 40868039)
29. Ballard CG, Greig NH, Guillozet-Bongaarts AL, Enz A, Darvesh S. Cholinesterases: roles in the brain during health and disease. Curr Alzheimer Res 2005; 2: 307-318. (Pubitemid 40980189)
30. Evans RT, Wardell J. On the identification and frequency of the J and K cholinesterase phenotypes in a Caucasian population. J Med Genet 1984; 21: 99-102. (Pubitemid 14155245)
31. Bartels CF, Jensen FS, Lockridge O, van der Spek AF, Rubinstein HM, Lubrano T et al. DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites. Am J Hum Genet 1992; 50: 1086-1103.
32. O'Brien KK, Saxby BK, Ballard CG, Grace J, Harrington F, Ford GA et al. Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics 2003; 13: 231-239. (Pubitemid 36543396)
33. Perry E, McKeith I, Ballard C. Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology 2003; 60: 1852-1853. (Pubitemid 36737093)
34. Lehmann DJ, Johnston C, Smith AD. Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. Hum Mol Genet 1997; 6: 1933-1936. (Pubitemid 27460370)
35. McIlroy SP, Crawford VL, Dynan KB, McGleenon BM, Vahidassr MD, Lawson JT et al. Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland. J Med Genet 2000; 37: 182-185. (Pubitemid 30245911)
36. Tilley L, Morgan K, Grainger J, Marsters P, Morgan L, Lowe J et al. Evaluation of polymorphisms in the presenilin-1 gene and the butyrylcholinesterase gene as risk factors in sporadic Alzheimer's disease. Eur J Hum Genet 1999; 7: 659-663. (Pubitemid 29424056)
37. Wiebusch H, Poirier J, Sevigny P, Schappert K. Further evidence for a synergistic association between APOE epsilon4 and BCHE-K in confirmed Alzheimer's disease. Hum Genet 1999; 104: 158-163. (Pubitemid 29123608)
38. Panegyres PK, Mamotte CD, Vasikaran SD, Wilton S, Fabian V, Kakulas BA. Butyrycholinesterase K variant and Alzheimer's disease. J Neurol 1999; 246: 369-370.
39. Singleton AB, Smith G, Gibson AM, Woodward R, Perry RH, Ince PG et al. No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease. Hum Mol Genet 1998; 7: 937-939. (Pubitemid 28221259)
40. Kehoe PG, Williams H, Holmans P, Wilcock G, Cairns NJ, Neal J et al. The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease. J Med Genet 1998; 35: 1034-1035. (Pubitemid 28534679)
41. Russ C, Powell J, Lovestone S, Holmes C. K variant of butyrycholinesterase and late-onset Alzheimer's disease. Lancet 1998; 351: 881. (Pubitemid 28121183)
42. Grubber JM, Saunders AM, Crane-Gatherum AR, Scott WK, Martin ER, Haynes CS et al. Analysis of association between Alzheimer disease and the K variant of butyrylcholinesterase (BCHE-K). Neurosci Lett 1999; 269: 115-119. (Pubitemid 29335426)
43. Alvarez-Arcaya A, Combarros O, Llorca J, Sanchez-Guerra M, Berciano J, Fernandez-Viadero C et al. The butyrylcholinesterase K variant is a protective factor for sporadic Alzheimer's disease in women. Acta Neurol Scand 2000; 102: 350-353.
44. Laws SM, Taddei K, Fisher C, Small D, Clarnette R, Hallmayer J et al. Evidence that the butyrylcholinesterase K variant can protect against late-onset Alzheimer's disease. Alzheimer's Rep 1999; 2: 219-223.
45. Lehmann DJ, Williams J, McBroom J, Smith AD. Using meta-analysis to explain the diversity of results in genetic studies of late-onset Alzheimer's disease and to identify high-risk subgroups. Neuroscience 2001; 108: 541-554. (Pubitemid 33660714)
46. Holmes C, Ballard C, Lehmann D, Smith AD, Beaumont H, Day IN et al. Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation. J Neurol Neurosurg Psychiatry 2005; 76: 640-643. (Pubitemid 40569672)
47. Darreh-Shori T, Almkvist O, Guan ZZ, Garlind A, Strandberg B, Svensson AL et al. Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002; 59: 563-572. (Pubitemid 34919991)
48. Bullock R, Bergman H, Touchon J, Gambina G, He Y, Nagel J et al. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Curr Med Res Opin 2006; 22: 483-494.
49. Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J et al. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease. Pharmacogenet Genom 2006; 16: 771-774. (Pubitemid 44632290)
50. Scacchi R, Gambina G, Moretto G, Corbo RM. Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with donepezil and rivastigmine. Am J Med Genet B 2009; 150B: 502-507.
51. Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
52. Hachinski VC, Lassen NA, Marshall J. Multi-infarct dementia. A cause of mental deterioration in the elderly. Lancet 1974; 2: 207-210.
53. Mahoney FI, Barthel DW. Functional evaluation: the Barthel Index. Md State Med J 1965; 14: 61-65.
54. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-1139. (Pubitemid 12051593)
55. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944. (Pubitemid 14076461)
56. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215.
57. Mullis KB, Faloona FA. Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol 1987; 155: 335-350.
58. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 1988; 239: 487-491. (Pubitemid 18084310)
59. Jensen FS, Nielsen LR, Schwartz M. Detection of the plasma cholinesterase K variant by PCR using an amplification-created restriction site. Hum Hered 1996; 46: 26-31. (Pubitemid 26002994)
60. Crook R, Hardy J, Duff K. Single-day apolipoprotein E genotyping. J Neurosci Methods 1994; 53: 125-127. (Pubitemid 24270522)
61. Vahidassr MD, Savage DS, Patterson CC, Lawson JT, Passmore AP. Carriage of apoE e4 lowers the age of onset of Alzheimer's disease in Northern Ireland. Alzheimer's Rep 2000; 3: 7-10.
62. Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997; 278: 1349-1356. (Pubitemid 27449696)
63. Tombaugh TN, McIntyre NJ. The Mini-Mental State Examination: a comprehensive review. J Am Geriatr Soc 1992; 40: 922-935.
64. Nadler JD, Relkin NR, Cohen MS, Hodder RA, Reingold J, Plum F. Mental status testing in the elderly nursing home population. J Geriatr Psychiatry Neurol 1995; 8: 177-183.
65. Eggers C, Herholz K, Hable E, Heiss WD. Cortical acetylcholine esterase activity and ApoE4-genotype in Alzheimer disease. Neurosci Lett 2006; 408: 46-50. (Pubitemid 44466200)
66. Lehmann DJ, Nagy Z, Litchfield S, Borja MC, Smith AD. Association of butyrylcholinesterase K variant with cholinesterase-positive neuritic plaques in the temporal cortex in late-onset Alzheimer's disease. Hum Genet 2000; 106: 447-452. (Pubitemid 30237513)
67. Tasker A, Ballard CG, Joachim C, Warden DR, Okello EJ, Perry RH et al. Butyrylcholinesterase K variant associated with higher enzyme activity in the temporal cortex of elderly patients. Neurosci Lett 2008; 442: 297-299.
68. Podoly E, Shalev DE, Shenhar-Tsarfaty S, Bennett ER, Ben Assayag E, Wilgus H et al. The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology. J Biol Chem 2009; 284: 17170-17179.